<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618394</url>
  </required_header>
  <id_info>
    <org_study_id>29042015</org_study_id>
    <nct_id>NCT03618394</nct_id>
  </id_info>
  <brief_title>Bone Turnover and Parenteral Nutrition</brief_title>
  <official_title>Early Bone Turnover Markers in Relation to Parenteral Nutrition Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iaso Maternity Hospital, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harokopio University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iaso Maternity Hospital, Athens, Greece</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of changes in biochemical markers of bone metabolism. Fat profile. Evaluation of
      the overall body development. Assessment of parenteral nutrition protocols.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteopenia is very common in premature infants, particularly in preterm infants born at
      extremely low birth weight This is probably related to inadequate calcium and phosphorus
      intake, which is considerably less than the accretion of these minerals during the last
      trimester of pregnancy In addition, severe morbidity during the neonatal period (e.g.
      bronchopulmonary dysplasia [BPD]), chronic drug therapy (e.g. diuretics and systemic
      steroids), the need for total parenteral nutrition and prolonged immobility increase the risk
      of bone demineralization.

      Total parenteral nutrition is associated with osteopenia in preterm infants. Insufficient
      calcium and phosphate are likely causes; aluminum contamination is another possible
      contributing factor as this adversely affects bone formation and mineralization.

      The DHA+ARA-supplemented formulas supported normal growth and bone mineralization in
      premature infants who were born at &lt;33 wk gestation. Smof lipid emulsion has a high density
      of this fatty acids, while Intra lipid does not contain any traces of DHA. Evidence has shown
      that long-chain polyunsaturated fatty acids (LCPUFA), especially the ω-3 fatty acids such as
      eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial for bone health and
      turnover.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in plasma calcium and osteocalcin levels</measure>
    <time_frame>20 days</time_frame>
    <description>Blood sample at 1st or 2nd (within 48 hours of birth) and 20th day of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in plasma DHA, EPA levels</measure>
    <time_frame>20 days</time_frame>
    <description>Blood sample at 1st or 2nd (within 48 hours of birth) and 20th day of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cange in plasma OPG levels</measure>
    <time_frame>20 days</time_frame>
    <description>Blood sample at 1st or 2nd (within 48 hours of birth) and 20th day of life</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">66</enrollment>
  <condition>Bone Turnover Rate Disorder</condition>
  <arm_group>
    <arm_group_label>Smoflipid</arm_group_label>
    <description>premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralipid</arm_group_label>
    <description>premature neonates receiving Soybean Based lipid emulsion</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCT/ω-3-PUFA</intervention_name>
    <description>lipid emulsion</description>
    <arm_group_label>Smoflipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soybean Based</intervention_name>
    <description>lipid emulsion</description>
    <arm_group_label>Intralipid</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Very Low Birth Weight preterm neonates with gestational age &lt;32 weeks
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age &lt;32 weeks

          -  birth weight &lt;1500g (VLBW infants)

          -  in need of Parenteral Nutrition support

        Exclusion Criteria:

          -  &gt;32 weeks of gestation

          -  chromosomal or other abnormalities

          -  parenteral nutrition &lt;80% of calorie/fluid needs

          -  primary liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Panos Papandreou</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>August 4, 2018</last_update_submitted>
  <last_update_submitted_qc>August 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iaso Maternity Hospital, Athens, Greece</investigator_affiliation>
    <investigator_full_name>Panos Papandreou</investigator_full_name>
    <investigator_title>Clinical Pharmacist, PharmD</investigator_title>
  </responsible_party>
  <keyword>preterms</keyword>
  <keyword>parenteral</keyword>
  <keyword>lipid</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

